Research programme: CtlP gene - Myriad PharmaceuticalsAlternative Names: CtlP gene research programme - Myriad Genetics
Latest Information Update: 10 Aug 2007
At a glance
- Originator Myriad Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 01 Jun 2000 Myriad Genetics has received a US patent for this research programme